INTRODUCTION
============

Cell growth and division in eukaryotes is controlled by a gene--protein regulatory network of immense complexity. To understand how this regulatory network governs the observed properties of proliferating cells requires mathematical models, which keep track of the myriad interactions controlling the process. Modeling approaches have proved helpful in unraveling the dynamics of cell proliferation in frog eggs,^[@bib1]^ fruit fly embryos,^[@bib2]^ fission yeast,^[@bib3]^ and budding yeast.^[@bib4; @bib5; @bib6; @bib7; @bib8; @bib9; @bib10]^ Mathematical models are not static objects; as new experimental data come to light, the models must be extended and improved.

In this paper we focus on cell cycle regulation in budding yeast, *Saccharomyces cerevisiae*. The molecular network regulating cell cycle progression in budding yeast ([Figure 1](#fig1){ref-type="fig"}), which is the foundation of our mathematical model, is the product of over 40 years of intensive study by molecular cell biologists starting in 1970 when Hartwell *et al*.^[@bib11; @bib12; @bib13]^ used classical genetics to dissect the budding yeast cell cycle into a semiordered sequence of events. The earliest event of this process Hartwell called START, when a budding yeast cell initiates in rapid succession the onset of DNA replication, the emergence of a new bud, and duplication of the spindle pole body (centrosome). Later, it was determined that some 'master' transcription factors are activated at the START transition.^[@bib14]^ After START, overlapping sequences of cell cycle events proceed simultaneously (DNA synthesis, migration of the nucleus to the bud neck, formation of an intranuclear spindle, congression of replicated chromosomes to the metaphase plate). Successful completion of these events is monitored at the metaphase checkpoint. When all systems are 'go', the yeast cell exits from mitosis (metaphase→anaphase→telophase→cell division). We subsume these processes under the title FINISH, because they return the mother and daughter cells to G1 phase, prepared to execute START of the next cell cycle.

The major goals of this paper are: (a) to build a mathematical model of the wiring diagram; (b) to confirm that the model accurately reproduces known characteristics of wild-type and mutant strains of budding yeast; and (c) to predict the phenotypes of novel combinations of mutant alleles.

RESULTS
=======

In the following subsections we discuss our model in light of the observed phenotypes of some selected strains carrying mutations in START and FINISH genes. Additional considerations are provided in the [Supplementary Text](#xob1){ref-type="supplementary-material"}. Unless otherwise stated, our model simulations are consistent with the observed phenotypes of these strains. Hence, all factual statements are confirmed by the references provided and by the simulations in the [Supplementary Information](#xob1){ref-type="supplementary-material"}.

Simulation of START mutants
---------------------------

### SBF and MBF mutants

SBF is a master cell cycle transcription factor composed of two components, Swi4 and Swi6, and inhibited by Whi5.^[@bib14],[@bib15]^ MBF is another important cell cycle transcription factor composed of Swi6 and Mbp1.^[@bib16]^ Mutant strains with a single-gene deletion of either *SWI4* or *MBP1* are viable, indicating that either SBF or MBF is sufficient for budding yeast cells to execute START.^[@bib15],[@bib17; @bib18; @bib19]^

Suppression of both SBF and MBF (e.g., in the strains *swi4Δ swi6Δ* or *swi4Δ mbp1Δ*) causes budding yeast cells to arrest before the START transition.^[@bib15]^ *whi5Δ* cells initiate SBF transcription prematurely; hence, they are smaller than wild-type cells.^[@bib20]^ *WHI5*^*OP*^ cells overexpress Whi5 and delay the START transition, dividing at a larger size than wild-type cells.^[@bib18]^ Deletion of *SWI6*, which encodes a common subunit of SBF and MBF, turns out to be viable and large, and *swi6Δ bck2Δ* cells are inviable.^[@bib14],[@bib19]^ We explain these observations by assuming that Swi4, with the help by Bck2, can function as SBF, although with less ability to activate transcription.

Targets of Cln3-dependent kinase include Swi6 and Whi5. Phosphorylation of either of these proteins activates SBF and initiates START.^[@bib17; @bib18; @bib19]^ Consequently, *cln3Δ* cells have an extended G1 phase and are larger than wild-type cells (1.85 times larger in our simulations). *cln3Δ whi5Δ* cells are as small as *whi5Δ*,^[@bib18]^ confirming that the major role of Cln3:Cdk1 in promoting START is phosphorylating Whi5. Additional deletion of *MBP1* in *cln3Δ* mutant cells has little effect on their phenotype; however, *cln3Δ swi4Δ* cells are inviable.^[@bib21]^ Because *swi4Δ* cells (which have only MBF activity) are viable, lethality of the double mutant strain, *swi4Δ cln3Δ*, indicates that Cln3:Cdk1 has a significant role in triggering both SBF and MBF activity.

Bck2 protein is another important activator of SBF and MBF transcription factors. Because *cln3Δ bck2Δ* cells arrest in early G1,^[@bib22],[@bib23]^ it appears that Cln3 and Bck2 perform some essential overlapping function(s) at the START transition. Viability of the triple deletion strain *cln3Δ bck2Δ whi5Δ* (ref. [@bib17]) suggests that this function involves removing Whi5 from SBF complexes. Model simulations agree with these experimental observations. These results confirm that Whi5 is a chief inhibitor of the START transition, and the main and essential target of both Cln3-dependent kinase and Bck2. The triple deletion strain *cln3Δ bck2Δ whi5Δ* is 1.48 times larger than wild-type cells because transcription of SBF-controlled promoters relies on non-phosphorylated Swi6:Swi4 complex, which is only moderately active in driving the synthesis of Cln1,2.

In cells lacking both *CLN3* and *BCK2*, Mbp1 is not phosphorylated and when bound to promoter it represses the background synthesis of Clb5,6. This assumption is supported by the observation that Mbp1 may function as a gene repressor.^[@bib24]^ That explains why the model predicts that the quadruple deletion strain, *cln3Δ bck2Δ whi5Δ mbp1Δ*, is slightly smaller than *cln3Δ bck2Δ whi5Δ* and only 30% larger than wild-type cells; see [Supplementary Table S8](#xob1){ref-type="supplementary-material"}. Other interesting predictions relate to the *swi4Δ mbp1Δ* strain, lacking both MBF and SBF, which is inviable even when either *CLN3* or *BCK2* are overexpressed. It is also not surprising that overexpression of *CLB5* rescues the lethality of *swi4Δ mbp1Δ* cells. The model also predicts that lethality of *swi4Δ mbp1Δ* cannot be rescued by deletion of either *SIC1* or *CDH1*. The *SIC1*-related prediction is indirectly supported by the fact that *swi4Δ swi6Δ sic1Δ* and *bck2Δ swi6Δ sic1Δ* strains (lacking both MBF and SBF activities) are inviable.^[@bib22],[@bib25]^

### Rescue of the inviable triple-cln deletion strain

The activation of SBF and MBF at START initiates the synthesis of Cln1,2 and Clb5,6 cyclins. These newly synthesized cyclins (in conjunction with Cdk1) enhance phosphorylation processes begun by Cln3-dependent kinase and/or Bck2 protein, thereby making the START transition irreversible. Once past START, the yeast cell is committed to DNA replication and budding. Another important role of Cln1,2-dependent kinases is to rid the cell of CKI, our designation for the stoichiometric inhibitors, Sic1 and Cdc6, of B-type cyclin-dependent kinases (Clb1--6:Cdk1). As CKI levels drop, Clb5,6-dependent kinase activities rise, initiating DNA replication and phosphorylating (inactivating) Cdh1. Inactivation of APC:Cdh1 allows the mitotic cyclins, Clb1 and Clb2, to accumulate, thereby preparing the cell for mitosis. This description is confirmed by the fact that cells lacking all three G1 cyclins, *cln1Δ cln2Δ cln3Δ*, arrest in G1,^[@bib26]^ but lethality of the triple-*cln* deletion strain can be rescued by additional deletion of *SIC1* (see [Supplementary Figure S2](#xob1){ref-type="supplementary-material"}).^[@bib27],[@bib28]^ Viability of *cln1Δ cln2Δ cln3Δ* cells can also be restored by overexpressing *CLB5*,^[@bib29],[@bib30]^ indicating high levels of Clb5 can overcome repression by Sic1. Interestingly, *SIC1* deletion is not sufficient to rescue *cln3Δ bck2Δ* cells.^[@bib22]^ Compared with triple-*cln* deletion cells, *cln3Δ bck2Δ* cells have significantly lower levels of Clb5,6 cyclins, as well as low levels of Cln1,2 cyclins. Hence, *cln3Δ bck2Δ sic1Δ* cells are unable to deactivate APC:Cdh1 (see [Supplementary Figure S2](#xob1){ref-type="supplementary-material"}).

We have tested whether deletion of *CDH1* can rescue the triple-*cln* deletion strain. Model simulations agree with observations that *cln1Δ cln2Δ cln3Δ cdh1Δ* cells pass START but arrest in telophase.^[@bib31]^ The model also agrees with the experimental observation that *cln1Δ cln2Δ cdh1Δ* cells are viable.^[@bib32]^ In addition, the model predicts that deletion of *CDH1* restores *cln1Δ cln2Δ* cells^[@bib33]^ almost to wild-type cell size. The model also predicts that *cln1Δ cln2Δ bck2Δ cdh1Δ* cells are viable and that *cln3Δ bck2Δ cdh1Δ* cells arrest in telophase.

Simulation of FINISH mutants
----------------------------

Exit from mitosis and return to G1 phase involves degradation of all B-type cyclins, Clb1--6, and activation of a phosphatase, Cdc14, that reverses the phosphorylations carried out by Clb-dependent kinases during S/G2/M.^[@bib34]^ *CDC14* is an essential gene in budding yeast, and *cdc14Δ* cells arrest in telophase. The activity of Cdc14 is tightly controlled by association with its inhibitory binding partner, Net1, which is located in the nucleolus.^[@bib35],[@bib36]^ Successful exit from mitosis requires that Cdc14 be released from the nucleolus to do its jobs in the nucleus and cytoplasm. Hence, genes involved in the FINISH transition are often identified by their effects on Cdc14 release from the nucleolus, which occurs in two consecutive steps: Cdc14 early anaphase release (FEAR)^[@bib9],[@bib37; @bib38; @bib39; @bib40]^ and the mitotic exit network (MEN).^[@bib36],[@bib38],[@bib40; @bib41; @bib42; @bib43]^

### FEAR mutants

In the absence of essential MEN components, cells exhibit only an early, partial release of Cdc14, enabled by the FEAR pathway: APC:Cdc20 ⊣ Pds1⊣ Esp1 ⊣ PPA2:Cdc55→Net1 ⊣ Cdc14. The FEAR pathway can be observed in isolation in strains in which MEN effectors, Cdc15 or Tem1, are deleted or substantially inhibited.^[@bib44],[@bib45]^ In [Figure 2](#fig2){ref-type="fig"} we simulate exit from mitosis, by *cdc20* block and release, in a wild-type genetic background ([Figure 2a](#fig2){ref-type="fig"}) and in a *cdc15Δ* cell ([Figure 2b](#fig2){ref-type="fig"}). The Cdc15-deficient cell arrests in telophase with high Clb2 level, because Cdc14 is only partially and transiently released from the nucleolus, in agreement with ref. [@bib45]. The FEAR pathway stifles itself by partially degrading mitotic cyclins and thereby quenching the phosphorylation of Net1 by Cdc5 and Clb-dependent kinase activities, leading to resequestration of Cdc14. MEN activity is needed to maintain Net1 in its phosphorylated state and Cdc14 released.

In the FEAR pathway, APC:Cdc20 activates Esp1 by degrading its stoichiometric inhibitor Pds1. If *PDS1* is deleted, then Esp1 is active, promoting early Cdc14 release and exit from mitosis.^[@bib46],[@bib47]^ Similarly, deletion of *CDC55* promotes early Cdc14 release, although *cdc55Δ* cells are viable.^[@bib48]^ Unsurprisingly, *cdc20Δ* cells arrest in metaphase with Cdc14 sequestered in the nucleus, but it is noteworthy that *PDS1* deletion does not rescue *cdc20Δ* cells.^[@bib49]^ To rescue *cdc20Δ* cells requires additional deletion of both *PDS1* and *CLB5*.^[@bib50]^ Viability of the *cdc20Δ pds1Δ clb5Δ* strain depends on the *CDH1* gene product.^[@bib50]^ The lethality of the *cdc20Δ pds1Δ* and *cdc20Δ pds1Δ clb5Δ cdh1Δ* strains^[@bib50]^ can be rescued by adding \~10 copies of the *SIC1* gene.^[@bib51]^ Our model simulations are consistent with all these phenotypes ([Supplementary Table S7](#xob1){ref-type="supplementary-material"}).

Despite the fact that early release of Cdc14 activates the MEN, it seems that the FEAR pathway is not essential for exit from mitosis. The FEAR pathway is blocked in *esp1Δ* cells and in *PDS1-dbΔ* cells (expressing a non-degradable form of Pds1, the stoichiometric inhibitor of Esp1).^[@bib45],[@bib52]^ Mutants lacking separase (Esp1) activity are inviable (or mitotic exit is substantially delayed) mainly because of Esp1's role as a protease to cleave cohesin rings, thereby initiating sister chromatid separation. This role of Esp1 can be replaced by TEV protease, which can be used to cleave cohesin molecules that have been engineered to carry the TEV protease recognition sequence. In this case, anaphase proceeds normally, activating the MEN while the FEAR pathway remains blocked.^[@bib42]^ In agreement with Lu and Cross,^[@bib42]^ our simulations ([Figure 3](#fig3){ref-type="fig"}) show that MEN activity is absolutely needed for mitotic exit, and FEAR is dispensable. The control ([Figure 3a](#fig3){ref-type="fig"}) shows how wild-type cells exit from mitosis after *cdc20* block and release, whereas *GAL-PDS1-dbΔ* cells (no FEAR, no MEN) arrest in metaphase ([Figure 3b](#fig3){ref-type="fig"}). By contrast, cells with functional MEN but no FEAR, *GAL-PDS1-dbΔ GAL-TEV*, are able to exit mitosis ([Figure 3c](#fig3){ref-type="fig"}). Whereas *cdc20*-blocked cells are not able to exit mitosis after expression of TEV protease ([Figure 3e](#fig3){ref-type="fig"}) because both FEAR and MEN pathways are inactive, overexpression of non-degradable Sic1 from a *GAL-SIC1-4A* gene promotes mitotic exit ([Figure 3f](#fig3){ref-type="fig"}) by the pathway Sic1 ⊣ Clb2 ⊣ Cdc15→MEN.

### MEN mutants

The MEN promotes sustained Cdc14 release by activating kinases that continue to phosphorylate Net1 as the activity of Clb2-kinase drops due to its degradation by Cdc20. The MEN kinase Cdc15 and its partner Tem1 integrate spatial and temporal cues to promote mitotic exit when the spindle poles are properly positioned and the metaphase-to-anaphase transition is executed. Cdc15 activity is inhibited by phosphorylation by Clb2:Cdk1^[@bib53]^ and activated by dephosphorylation by Cdc14.^[@bib54]^ Thus, partial degradation of Clb2 by APC:Cdc20 in anaphase and partial release of Cdc14 by the FEAR pathway in anaphase together promote activation of the MEN. Tem1 is kept inactive by Bfa1.^[@bib55],[@bib56]^ Bfa1's regulatory partner, Bub2, is inactivated by phosphorylation by Cdc5 and activated by dephosphorylation by Cdc14.^[@bib39]^ Notice that, even as MEN promotes Cdc14 release, Cdc14 phosphatase feeds back on MEN activity by an incoherent signaling pathway: Cdc14 activates MEN effector kinases by dephosphorylating Cdc15, but Cdc14 inactivates MEN effector kinases by activating Bfa1:Bub2 (see the MEN module in [Figure 1](#fig1){ref-type="fig"}). The dynamical consequences of these complex interactions demand mathematical modeling.

Deletion of both *BUB2* and *BFA1* is not lethal,^[@bib57]^ whereas deletion of *CDC15* or *CDC5* or *TEM1* is lethal.^[@bib44],[@bib58]^ Overexpression of *CDC15* rescues the *tem1Δ* strain, but overexpression of *TEM1* does not rescue *cdc15Δ* cells, suggesting that Cdc15 has some activity, independent of Tem1, in regulating Cdc14 release. To account for this fact in our model, Cdc15 phosphorylates Net1 both in conjunction with Tem1 (MEN variable) and independent of Tem1 (see the RENT module in [Figure 1](#fig1){ref-type="fig"}). Reducing the level of Net1, using temperature-sensitive alleles of the *NET1* gene, rescues both *tem1Δ* and *cdc15Δ* strains.^[@bib35]^ The *cdc15Δ* strain can also be rescued by overexpressing *CDC14*. Our model is consistent with all these phenotypes. Another interesting MEN mutant is *net1*^*ts*^ *cdc15Δ cdh1Δ*, whose viability^[@bib59]^ is accounted for by our model but not by others, to our knowledge.

Cdc5 is a key regulator of the FINISH transition because of the roles it has in activating the MEN and in the release of Cdc14 from its inhibitor, Net1, in the nucleolus (see the MEN and RENT modules in [Figure 1](#fig1){ref-type="fig"}). Notice that Cdc14 release requires the combined activity of two different kinases: Cdc5 and either MEN or Clb2:Cdk1. Successful exit from mitosis requires that Cdc14 be released from the nucleolus to do its jobs in the nucleus and cytoplasm. Not surprisingly, *CDC5* deletion is lethal. *CDC5* overexpression, on the other hand, promotes Cdc14 release from the nucleolus even in the absence of both MEN and FEAR functions ([Figure 4](#fig4){ref-type="fig"}). Simulations agree with experimental data^[@bib37],[@bib60]^ that *GAL-CDC5* rescues lethality of *cdc15Δ* strain ([Figure 4a](#fig4){ref-type="fig"}) and promotes Cdc14 release in *GAL-PDS1-dbΔ cdc20Δ* cells ([Figure 4b](#fig4){ref-type="fig"}), in cells treated with nocodazole ([Figure 4c](#fig4){ref-type="fig"}), and in hydroxyurea-arrested cells ([Figure 4d](#fig4){ref-type="fig"}).

### Cdc14 Oscillations

Once Cdc14 is fully released, it dephosphorylates Cdh1P, thereby activating APC:Cdh1, which polyubiquitinates Cdc5, labeling it for destruction.^[@bib61; @bib62; @bib63]^ The degradation of Cdc5 causes Cdc14 to be resequestered in the nucleolus.^[@bib62]^ It has been observed by two groups independently that the release and resequestration of Cdc14 in budding yeast can cycle periodically when Clb2:Cdk1 activity is maintained at a high level by using a non-degradable form of Clb2.^[@bib7],[@bib64]^ Cdc14 'endocycles' are a consequence of a negative-feedback loop in the MEN (Cdc5 ⊣ Net1 ⊣ Cdc14→Cdh1 ⊣ Cdc5), as demonstrated by simple mathematical models.^[@bib7],[@bib8],[@bib64]^ But is this simple picture consistent with everything else known about exit-from-mitosis in budding yeast? Can Cdc14 endocycles be reproduced by a more comprehensive model that is consistent with the observed phenotypes of all exit-from-mitosis mutants? In light of this question, reproducing Cdc14 endocycles becomes an important test for our model.

In [Figure 5a](#fig5){ref-type="fig"} we show that our wide-ranging model of exit from mitosis reproduces Cdc14 endocycles in the mutant strain, *GAL-CLB2-dbΔ*, where they were first observed. The period of oscillation is \~70 min, in agreement with experimental observations.^[@bib7]^

As expected for cells carrying the *GAL-CLB2-dbΔ* gene, Clb2 level is very high when the cells are growing in galactose, and the sustained high level of Clb2 arrests these cells in telophase. For *GAL-CLB2-dbΔ* we set the degradation rate constant of Clb2 by APC:Cdh1 to 37% of that for wild-type cells. In this case, periodic Cdc14 release causes oscillations of Clb2 as well as Cdh1 and Cdc5. Although Clb2 oscillates, its level remains high, because Clb2 is rapidly and constitutively synthesized and only partially degraded in *GAL-CLB2-dbΔ* cells. Our model also predicts that the frequency of Cdc14 endocycles ([Figure 5b](#fig5){ref-type="fig"}) increases linearly over a range of Clb2 levels: \[Clb2\] large enough to sustain mitotic arrest but not so large as to cause constitutive Cdc14 release.

Because Cdc14 oscillations are observed in *GAL-CLB2*^*nd*^ cells, lacking both destruction and KEN boxes of Clb2, the degradation of Clb2 by APC:Cdh1 is not necessary for oscillations; see ref. [@bib64] and [Figure 5c](#fig5){ref-type="fig"}. Although *GAL-CLB2*^*nd*^ cells continue to synthesize endogenous Clb2, it is quickly degraded by the high level of APC:Cdh1. Hence, the endogenous fraction of Clb2 accounts for only a small amplitude oscillatory component on top of the constant high level of non-degradable Clb2. The simulated dependence of oscillation frequency on \[Clb2\] in this strain ([Figure 5d](#fig5){ref-type="fig"}) agrees well with observed trends.^[@bib64]^

Using the model for predictive purposes, we find that Cdc14 endocycles are likely to be observed in strains carrying the *GAL-CLB2-dbΔ* gene in combination with: *cdc15*^*as1*^*, swi5Δ*, *cdc20-3,* or *pds1Δ cdc20Δ clb5Δ* ([Supplementary Figures S3A--D](#xob1){ref-type="supplementary-material"}); but they are absent when *GAL-CLB2-dbΔ* is combined with *cdc5-1, CDC5-dbΔ, cdh1Δ,* or *cdc14-1* ([Supplementary Figures S4A--D](#xob1){ref-type="supplementary-material"}). Thus, we conclude that Cdc14 endocycles will be abolished in *GAL-CLB2-dbΔ* strains if the negative-feedback loop Cdc5 ⊣ Net1 ⊣ Cdc14→Cdh1 ⊣ Cdc5 is interrupted but persist when other genes of the FINISH transition are deleted (e.g., *cdc15Δ*, *sic1Δ*, *swi5Δ*, *pds1Δ*, *cdc20Δ*).

DISCUSSION
==========

Using a new approach for modeling gene--protein regulatory networks in a modular manner, we have reformulated and extended earlier models of the START and FINISH transitions in the cell division cycle of *Saccharomyces cerevisiae*. Exploiting a natural separation of time scales in these networks, the new modeling approach classifies reactions into three basic types: (1) protein synthesis and degradation (slow); (2) protein modification, e.g., phosphorylation and dephosphorylation (moderate); and (3) multi-protein complex formation (fast). This classification allows considerable latitude in describing biochemically realistic networks, while limiting the number of adjustable parameters that must be estimated from the data. The modularity of the scheme allows the model to be quickly and easily extended to encompass new aspects of the control mechanism without drastically disturbing the ancestral model and its legacy parameter values. In our experience, the 'standard component' modeling strategy^[@bib65]^ has all these advantages.

Our standard-component model of the budding yeast cell cycle successfully accounts for the observed phenotypes of 257 yeast strains carrying mutant alleles of cell cycle genes in various combinations (from a test collection of 263 strains). The good agreement of simulation results with experimental data is strong evidence confirming our hypothetical regulatory mechanism of cell cycle control in budding yeast ([Figure 1](#fig1){ref-type="fig"}). We have used the model to predict the phenotypes of 30 mutant strains that were not included in our test collection of 263 strains. Some of the most interesting predictions are listed in [Table 1](#tbl1){ref-type="table"}. Three of these predictions are already confirmed by published experiments, and two novel strains have been created and phenotyped by our collaborators (Adames & Peccoud, private communication). One prediction was not confirmed, suggesting that Whi5 has a role inhibiting MBF, a possibility not included in our model.

In putting forward this mechanism, we focused our attention on the genes and proteins affecting the START and FINISH transitions, because recent experimental results on these transitions have necessitated revisions of our previous model of the yeast cell cycle.^[@bib5]^ In particular, our revised model captures the appearance of Cdc14 endocycles in mutant strains that are arrested in metaphase by high levels of the mitotic cyclin Clb2. Although Cdc14 endocycles have been simulated by simplified models of the FEAR pathway,^[@bib7],[@bib8],[@bib64]^ they have not appeared (until now) in models that attempt a more comprehensive account of the entire cell cycle of budding yeast. Using our model, we have predicted the presence or absence of Cdc14 endocycles in mutant strains that combine Clb2 overexpression with the deletion of other genetic elements of the FINISH transition. These simulations support a 'two-hit' mechanism, whereby Cdc14 release requires the combined activity of two different kinases: Cdc5 and either MEN kinase or mitotic cyclin-dependent kinase.

Although our model is consistent with the diverse phenotypes of \>250 experimentally characterized mutant strains, only a small fraction of the possible combinations of mutant alleles have been experimentally characterized to date. Hence, our model, to the extent that it is an accurate portrayal of the cell cycle control system in yeast, could be a useful tool to predict the phenotypes of an enormous number of yeast strains that are yet to be studied experimentally. Just to simulate strains with combinations of deletion and overexpression alleles of up-to-five genetic loci will provide predictions of \>20 million phenotypes, of which only about 300 have been studied experimentally. We are currently undertaking this calculation, and we will sift through the predictions for the most interesting and informative strains that can be tested experimentally. For example, strains lacking many genes but retaining viability may be especially helpful in understanding the molecular mechanism of cell cycle control. Also, by classifying predictions as robust or fragile (see [Supplementary Text](#xob1){ref-type="supplementary-material"} and [Supplementary Figure S5](#xob1){ref-type="supplementary-material"}), we will provide a further criterion for prioritizing experimental tests of the model.

MATERIALS AND METHODS
=====================

In the [Supplementary Text](#xob1){ref-type="supplementary-material"}, we describe the modeling approach^[@bib65]^ used to formulate the differential-algebraic equations set forth in [Supplementary Tables S1--S3](#xob1){ref-type="supplementary-material"}. [Supplementary Table S4](#xob1){ref-type="supplementary-material"} lists the 293 mutant strains simulated in this study, and [Supplementary Table S5](#xob1){ref-type="supplementary-material"} records the parameter changes used to simulate these mutations. [Supplementary Tables S6 and S7](#xob1){ref-type="supplementary-material"} summarize the observed phenotypes of the START and FINISH mutant strains discussed in the main text, and [Supplementary Table S8](#xob1){ref-type="supplementary-material"} summarizes the model's predicted phenotypes of novel mutant strains.

The model and all simulations reported in this paper are implemented in the Virtual Cell and in our lab's custom-built software, PET.^[@bib66]^ In the Virtual Cell Database (VCell DB) our model is found under MathModels: PublicMathModels: pavelkr: BuddingYeastCellCycle_2015. PET software can be downloaded freely from <http://mpf.biol.vt.edu/pet/>, and the pet file needed to run our model can be downloaded from the site <http://mpf.biol.vt.edu/research/start_to_finish/>. That site also provides a pdf containing simulations of wild-type cells and all 293 mutant strains. The model can be explored with an online simulator at <http://sbmlsimulator.org/simulator/2>. In [Figure 6](#fig6){ref-type="fig"} we present, for reference, the simulation of a wild-type daughter cell growing in glucose, and in [Supplementary Figure S1](#xob1){ref-type="supplementary-material"} we present simulations of three inviable mutant strains.
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![Proposed mechanism of cell cycle regulation in budding yeast: (top) overview; (bottom) mechanistic details of the 'modules'. Solid arrows represent reactions of synthesis, degradation, complex formation, phosphorylation and dephosphorylation, and translocations. The rectangle+oval icon represents a protein complex, and the four small ovals represent end-products of proteolysis reactions. Dashed lines with arrowhead or bar head represent, respectively, activation or inhibition of a reaction, a substance, or a module by a substance or a module. Also a protein name written along a reaction arrow indicates the catalysis of the reaction by the protein. To simplify the model, we combine cyclins with similar functions: Cln1+Cln2='Cln2', Clb5+Clb6='Clb5', and Clb1+Clb2='Clb2'. The kinase partner, Cdk1, of each cyclin is not indicated in the diagram, because we assume (justifiably) that Cdk1 is in excess and that it combines rapidly and strongly with any available cyclin molecules. Cln2, Clb5, and Clb2 are primarily responsible for initiating bud formation, DNA synthesis and mitosis, respectively, although there is some overlap of function among these cyclin-dependent kinases. The cyclin-dependent kinase inhibitor, CKI, refers to both Sic1 and Cdc6, which are stoichiometric inhibitors of Clb-dependent kinases. For a full and precise description of the model, see the set of kinetic equations in [Supplementary Table S2](#xob1){ref-type="supplementary-material"}.](npjsba201516-f1){#fig1}

![Cdc14 early anaphase release (FEAR) in *cdc15Δ* cells. (**a**) Control cells (*cdc20Δ GAL-CDC20*) are synchronized in metaphase by pre-simulation for 135 min in the absence of Cdc20, then Cdc20 is added back at *t*=0. These cells exit mitosis normally. (**b**) When cells lacking Cdc15 are treated the same way, Cdc14 is released only for a short time. Without MEN support, Cdc14 quickly returns to the nucleolus because, as Clb2 drops, Net1 is reactivated and Cdc14 becomes resequestered. This transient release of Cdc14 agrees well with observations shown on [Figure 1b](#fig1){ref-type="fig"} of ref. [@bib45]. MEN, mitotic exit network.](npjsba201516-f2){#fig2}

![Cdc14 release in strains carrying *GAL-PDS1-dbΔ* or *GAL-SIC1-4A*. These simulations are comparable to [Figure 1](#fig1){ref-type="fig"} of ref. [@bib42]. (**a**) Control; same as [Figure 2a](#fig2){ref-type="fig"}. (**b**) In the mutant strain expressing a non-degradable version of Pds1 (securin), when Cdc20 is activated, Clb2 is only partially degraded, and the FEAR pathway (Pds1⊣ Esp1 ⊣ PPA2:Cdc55→Net1 ⊣ Cdc14) is inhibited. Consequently, Cdc14 remains sequestered in nucleolus, Cdh1:APC is not fully activated, and the cell cannot exit from mitosis. (**c**) Nonetheless, if cohesin molecules are cleaved by TEV protease, then the spindle position checkpoint can be turned off and the MEN pathway activated, promoting Cdc14 release and exit from mitosis, even though the FEAR pathway is blocked by non-degradable Pds1. (**d**,**e**) Cdc14 is not released in cells carrying either the *GAL-SIC1-4A* gene (encoding non-degradable Sic1) or the *GAL-TEV* construct, but (**f**) Cdc14 is released in cells carrying both *GAL-SIC1-4A* and *GAL-TEV*.](npjsba201516-f3){#fig3}

![The roles of Polo kinase (Cdc5) in mitotic exit. (**a**) Overexpression of Cdc5 rescues the lethality of *cdc15Δ* cells, which lack MEN-dependent kinase activity. (**b**,**c**) Overexpression of Cdc5 promotes Cdc14 release in cells with blocked FEAR pathway, either by non-degradable Pds1 or by nocodazole. (**d**) Overexpression of Cdc5 promotes Cdc14 release in hydroxyurea-treated cells. These simulations agree well with experimental observations.^[@bib37]^ MEN, mitotic exit network.](npjsba201516-f4){#fig4}

![Cdc14 endocycles. (**a**) When grown in galactose, *GAL-CLB2-dbΔ* cells express a mutant form of Clb2 that is not degraded by APC:Cdc20 and only weakly degraded by APC:Cdh1 (37% of that for the wild-type protein). Because these cells maintain a high level of Clb2-kinase activity, they cannot exit mitosis, and yet they exhibit regular oscillations of Cdc14 release and resequestration (period=73 min). (**b**) The frequency of Cdc14 endocycles depends linearly on Clb2 level. (**c**,**d**) Similar oscillations in Cdc14 release are exhibited by the *GAL-CLB2*^*nd*^ strain. The *CLB2*^*nd*^ allele encodes Clb2 protein that is not degraded by either APC:Cdc20 or APC:Cdh1. The simulations in this figure agree well with experimental observations in refs [@bib7],[@bib64].](npjsba201516-f5){#fig5}

![The cell cycle of a wild-type daughter cell in glucose medium. Cell size (mass) increases exponentially (mass-doubling time=90 min). The cell divides at a size of 2.37 (arbitrary units) into a smaller daughter cell (size=1.09) and a larger mother cell (size=1.28). Following the time-course of daughter cells over three generations, we plot the rise and fall of certain key cell cycle regulators in **a**, **b**. The cycle time of daughter cells in this simulation is 100 min. One arbitrary unit of cell size=33pg=30 fL.](npjsba201516-f6){#fig6}

###### Predicted phenotypes of some mutant strains

  *Mutant genotype*                                                                                    *Predicted phenotype*[a](#t1-fn1){ref-type="fn"}   *Confidence*[b](#t1-fn2){ref-type="fn"}   *Experimental evidence*
  --------------------------------------------------------------------------------------------------- -------------------------------------------------- ----------------------------------------- -------------------------
  *cln1Δ cln2Δ swi4Δ*                                                                                                      Inviable                                       Robust                      Inviable^[@bib14]^
  *cln1Δ cln2Δ mbp1Δ*                                                                                                       Viable                                        Fragile                    Viable (unpublished)
  *cln1Δ cln2Δ cln3Δ cdc6Δ sic1Δ*                                                                                           Viable                                        Fragile                            None
  *cln1Δ cln2Δ cln3Δ whi5Δ*                                                                                                Inviable                                       Robust                      Inviable^[@bib17]^
  *cln3Δ swi4Δ whi5Δ*                                                                                                      Inviable                                       Robust                             None
  *swi4Δ mbp1Δ whi5Δ*                                                                                                      Inviable                                       Robust                     Viable (unpublished)
  *swi4Δ mbp1Δ sic1Δ*                                                                                                      Inviable                                       Fragile                            None
  *swi4Δ mbp1Δ cdh1Δ*                                                                                                      Inviable                                       Fragile                            None
  *swi4Δ mbp1Δ GAL-BCK2*                                                                                                   Inviable                                       Robust                      Inviable^[@bib22]^
  *swi4Δ mbp1Δ GAL-CLN3*                                                                                                   Inviable                                       Robust                             None
  *swi4Δ mbp1Δ GAL-CLB5*                                                                                                    Viable                                        Robust                             None
  *mbp1*Δ *mcm1*Δ *swi4*Δ *swi5*Δ *swi6*Δ *GAL-CLB2 GAL-CDC5 GAL-CDC20 GAL-CLN2(low) GAL-SIC1(low)*                         Viable                                        Fragile                            None

None of these mutant strains were included in the collection of 263 strains used to parametrize the model.

Robustness analysis of predicted phenotypes is described in the [Supplementary Text](#xob1){ref-type="supplementary-material"}.
